Skip to main content
High RiskFDAfda-D-0327-2018MISLABELED

Laroscorbine Platinum Vitamin C 1 gm Collagen 0.35 gm, Roche

Category
Units Affected
0
Recall Date
January 19, 2018
Issuing Agency
Hazard
Mislabeled

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-D-0327-2018.

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-D-0327-2018.

Recall terminated by FDA.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact Flawless Beauty Llc or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-D-0327-2018.

Flawless Beauty LLC

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

Flawless Beauty Llc Recall FAQ

Flawless Beauty Llc is the subject of a supplements safety report: Laroscorbine Platinum Vitamin C 1 gm Collagen 0.35 gm, Roche. The notice was published on January 19, 2018 by the U.S. Food and Drug Administration (FDA). Approximately 0 units are potentially affected.